Pitanga
Av. Presidente Juscelino Kubitschek 2041/2235 - Vila Olimpia, São Paulo, SP, 04543-011, Brazil
Overview
The Pitanga Fund invests in innovative companies with high growth potential. The fund's goal is to work with early stage start-ups and to help entrepreneurs with innovative ideas to build their business. The innovation that the firm wishes to support involves innovative business models or the development and deployment of new technologies. Pitanga looks for businesses that aim to address large markets and can capture a significant fraction of these markets in a short time. To achieve these goals the companies must deploy a set of innovations capable of generating a wide competitive advantage. If these conditions are met, Pitanga is prepared to provide the capital necessary to develop and implement new technologies or business models. The firm contributes the necessary capital and is prepared to provide assistance by participating on the board of directors. Pitanga Fund has no limitations regarding sectors or geographies. However, prefers to invest in Brazilian companies or companies that have a significant presence in Brazil. Over the next four years Pitanga intends to invest in a limited number of companies, these will be chosen via a rigorous selection process.
- Total investments
- 3
- Lead investments
- 3
- Investments · 12mo
- 1
- Active investors
- 5
Sector focus
- Venture Capital
Investment portfolio
- Terra Genomics
Led · Seed · Jul 2026
Terra Genomics develops next-generation bioinputs by combining artificial intelligence and bioengineering for agricultural applications. The company aims to build a global biotechnology business originating in Brazil and emphasized its intent to convert investor confidence into scientific progress and agricultural impact. It announced a R$18 million Seed round to support those efforts. Terra Genomics has recruited a Scientific Advisory Board featuring Fernando Reinach and Gonçalo Pereira. The article did not disclose specific revenues, user metrics, or founding year.
- Nintx
Led · Series A · Dec 2024
Nintx develops a new generation of multi-target medicines derived from Brazilian biodiversity, focusing on multifactorial diseases mediated in part by the human gut microbiome. Its proprietary platforms include xGI biomics®, which simulates the gastrointestinal system, and GAIA path®, a knowledge-graph analytics tool mapping plants, natural products, biological targets, the microbiome and diseases. The company advances programs through preclinical development with a plan to license candidates to large pharmaceutical companies for clinical development and commercialization, targeting the first licensing within three years. Near-term plans include accelerating R&D of eight drug programs (many in partnership with companies such as Adeste and Centroflora and research institutions including CIEnP and CNPEM/Sirius), hiring researchers, introducing new technologies, and expanding its laboratory. Financially, Nintx completed a $10M Series A and previously raised a $3M seed in 2022; the Series A is complemented by a $2.5M grant from FINEP. The company also announced a C‑suite restructuring with Stephani Saverio becoming CEO in January 2025.
- Collokia
Led · Seed · Jun 2016
Collokia develops a machine-learning based collaboration platform that runs plugins in users' natural work environments to collect information, identify patterns, and map employee decision-making. Its algorithms analyze collective experience to automatically connect people with colleagues, research, solutions and sources of knowledge when needed. The platform has been in development and testing since 2014 and is currently available to beta customers. The company plans to expand commercial operations and continue building out the platform for key vertical markets, starting with the IT development industry. Collokia was founded in 2014 by Pablo Brenner (former Global VP of Innovation at Globant) and Jayson Minard (former Technologist at Prezi and CTO at AbeBooks). The company is based in Montevideo, Uruguay and San Francisco, CA.